AR087615A1 - Moleculas biespecificas de union a antigeno - Google Patents
Moleculas biespecificas de union a antigenoInfo
- Publication number
- AR087615A1 AR087615A1 ARP120103070A ARP120103070A AR087615A1 AR 087615 A1 AR087615 A1 AR 087615A1 AR P120103070 A ARP120103070 A AR P120103070A AR P120103070 A ARP120103070 A AR P120103070A AR 087615 A1 AR087615 A1 AR 087615A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding molecule
- bispecific antigen
- antigen
- fab fragment
- replaced
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 9
- 102000036639 antigens Human genes 0.000 title abstract 9
- 108091007433 antigens Proteins 0.000 title abstract 9
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Reivindicación 1: Molécula biespecífica de unión a antígeno, que comprende un primer fragmento Fab que se une específicamente a un primer antígeno, un segundo fragmento Fab que se une específicamente a un segundo antígeno, y un dominio Fc compuesto de una primera y segunda subunidades capaces de asociación estable, en la que: a) la molécula biespecífica de unión a antígeno proporciona unión monovalente al primer y/o segundo antígenos, b) el primer fragmento Fab, el segundo fragmento Fab y la primera subunidad del dominio Fc se fusionan entre sí, y c) en el primer y/o en el segundo fragmentos Fab se lleva a cabo una de las sustituciones siguientes: (i) los dominios variables VL y VH se sustituyen uno por otro, (ii) los dominios constantes CL y CH1 se sustituyen uno por otro, o (iii) los dominios variables y constantes VL-CL y VH-CH1 se sustituyen unos por otros, con la condición de que no se lleve a cabo la misma sustitución en el primer y en el segundo fragmentos Fab. Reivindicación 32: Polinucleótido aislado codificante de la molécula biespecífica de unión a antígeno según cualquiera de las reivindicaciones 1 a 31, o un fragmento de la misma. Reivindicación 33: Vector de expresión que comprende el polinucleótido aislado según la reivindicación 32. Reivindicación 36: Composición farmacéutica que comprende la molécula biespecífica de unión a antígeno según cualquiera de las reivindicaciones 1 a 31 y un portador farmacéuticamente aceptable. Reivindicación 40: Utilización de la molécula biespecífica de unión a antígeno según cualquiera de las reivindicaciones 1 a 31, para la preparación de un medicamento destinado al tratamiento de una enfermedad en un individuo que necesita del mismo. Reivindicación 42: Utilización según la reivindicación 40 o método según la reivindicación 41, en la que dicha enfermedad es el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11178371 | 2011-08-23 | ||
| EP12168189 | 2012-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087615A1 true AR087615A1 (es) | 2014-04-03 |
Family
ID=46800168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103070A AR087615A1 (es) | 2011-08-23 | 2012-08-22 | Moleculas biespecificas de union a antigeno |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20130058937A1 (es) |
| EP (1) | EP2748202B1 (es) |
| JP (1) | JP5925893B2 (es) |
| KR (1) | KR101721301B1 (es) |
| CN (1) | CN103764681B (es) |
| AR (1) | AR087615A1 (es) |
| AU (4) | AU2012298535A1 (es) |
| BR (1) | BR112014003598B1 (es) |
| CA (1) | CA2844538C (es) |
| DK (1) | DK2748202T3 (es) |
| ES (1) | ES2686327T3 (es) |
| HK (1) | HK1197249A1 (es) |
| HR (1) | HRP20181355T1 (es) |
| HU (1) | HUE039703T2 (es) |
| IL (1) | IL230553B (es) |
| LT (1) | LT2748202T (es) |
| MX (1) | MX349095B (es) |
| MY (1) | MY171038A (es) |
| PL (1) | PL2748202T3 (es) |
| PT (1) | PT2748202T (es) |
| RS (1) | RS57744B1 (es) |
| RU (1) | RU2650775C2 (es) |
| SG (1) | SG2014008577A (es) |
| SI (1) | SI2748202T1 (es) |
| WO (1) | WO2013026831A1 (es) |
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266967B2 (en) * | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体 |
| KR101456326B1 (ko) | 2009-04-07 | 2014-11-12 | 로슈 글리카트 아게 | 3가, 이중특이적 항체 |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| CN104945509A (zh) | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| BR112013013311A2 (pt) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
| EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| EP2681239B8 (en) | 2011-02-28 | 2015-09-09 | F. Hoffmann-La Roche AG | Antigen binding proteins |
| EP2681240B1 (en) | 2011-02-28 | 2017-08-16 | F. Hoffmann-La Roche AG | Monovalent antigen binding proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| RU2605390C2 (ru) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения |
| BR112014019579A2 (pt) | 2012-02-10 | 2019-10-15 | Genentech, Inc | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| RU2639287C2 (ru) | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
| KR20150064068A (ko) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법 |
| WO2014079000A1 (en) | 2012-11-21 | 2014-05-30 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| EP3444278A1 (en) | 2013-02-26 | 2019-02-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| DK2961771T3 (da) | 2013-02-26 | 2020-03-02 | Roche Glycart Ag | Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA |
| RU2015140917A (ru) * | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| EP2970485A1 (en) * | 2013-03-15 | 2016-01-20 | Merck Patent GmbH | Tetravalent bispecific antibodies |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
| CA2925677A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Bispecific her2 antibodies and methods of use |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| TWI726842B (zh) | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
| MX2016014434A (es) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion. |
| BR112016030740A2 (pt) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | diacorpos heterodiméricos biespecíficos e seus usos |
| WO2016020309A1 (en) | 2014-08-04 | 2016-02-11 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| MX2017006626A (es) * | 2014-11-20 | 2017-08-21 | Hoffmann La Roche | Cadenas ligeras comunes y metodos de uso. |
| RS61134B1 (sr) | 2014-11-20 | 2020-12-31 | Hoffmann La Roche | Kombinovana terapija bispecifičnim antigen vezujućim molekulima koji aktiviraju t ćelije za cd3 i folatni receptor 1 (folr1), i antagonistima vezivanja ose pd-1 |
| ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
| WO2016153572A1 (en) * | 2015-03-25 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
| HRP20220304T1 (hr) | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferinska receptorska protutijela s prilagođenim afinitetom |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| PE20181004A1 (es) | 2015-10-02 | 2018-06-26 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
| RS62450B1 (sr) | 2015-10-02 | 2021-11-30 | Hoffmann La Roche | Anti-pd1 antitela i postupci primene |
| JP7044700B2 (ja) | 2015-10-02 | 2022-03-30 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子 |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| JP6925278B2 (ja) | 2015-11-18 | 2021-08-25 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| CN115920030A (zh) | 2015-12-09 | 2023-04-07 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
| CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
| AU2017209099A1 (en) | 2016-01-22 | 2018-08-02 | Janssen Biotech, Inc. | Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same |
| NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
| PL3433280T3 (pl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | Dwuswoiste cząsteczki limfocytów T aktywowane przez proteazy |
| WO2018035084A1 (en) | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| JOP20190100A1 (ar) * | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| CN110494452B (zh) | 2017-04-03 | 2023-08-25 | 豪夫迈·罗氏有限公司 | 结合steap-1的抗体 |
| MX2019011916A (es) | 2017-04-05 | 2020-01-09 | Hoffmann La Roche | Anticuerpos anti-lag3. |
| KR102346336B1 (ko) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
| CN111246885A (zh) | 2017-10-20 | 2020-06-05 | 豪夫迈·罗氏有限公司 | 从单特异性抗体生成多特异性抗体的方法 |
| TWI832824B (zh) | 2017-10-30 | 2024-02-21 | 瑞士商赫孚孟拉羅股份公司 | 自單特異性抗體於活體內產生多特異性抗體之方法 |
| TWI805665B (zh) | 2017-12-21 | 2023-06-21 | 瑞士商赫孚孟拉羅股份公司 | 結合hla-a2/wt1之抗體 |
| JP7074859B2 (ja) | 2017-12-22 | 2022-05-24 | エフ．ホフマン－ラ ロシュ アーゲー | 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法 |
| CN111479588A (zh) | 2017-12-29 | 2020-07-31 | 豪夫迈·罗氏有限公司 | 用于改善抗vegf抗体的vegf受体阻断选择性的方法 |
| WO2019149715A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Stabilized immunoglobulin domains |
| US20200354457A1 (en) | 2018-01-31 | 2020-11-12 | Hoffmann-La Roche Inc. | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| WO2019191552A1 (en) | 2018-03-29 | 2019-10-03 | Genentech, Inc. | Modulating lactogenic activity in mammalian cells |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| SG10202105788SA (en) | 2018-12-21 | 2021-06-29 | Hoffmann La Roche | Antibodies binding to cd3 |
| BR112021012338A2 (pt) | 2018-12-24 | 2021-09-14 | Sanofi | Proteínas de ligação multiespecíficas com domínios fab mutantes |
| CN113412123A (zh) | 2018-12-28 | 2021-09-17 | 豪夫迈·罗氏有限公司 | 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白 |
| CN113490690A (zh) * | 2018-12-29 | 2021-10-08 | 南通壹宸生物医药科技有限公司 | 异源二聚体融合蛋白 |
| EP3980130A1 (en) * | 2019-06-06 | 2022-04-13 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| AU2020296247A1 (en) | 2019-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| MX2021015648A (es) | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| JP7450647B2 (ja) | 2019-06-26 | 2024-03-15 | エフ． ホフマン－ラ ロシュ アーゲー | Ｓｉｒｔ－１遺伝子ノックアウトを有する哺乳類細胞株 |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| WO2021018925A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
| BR112022001460A2 (pt) | 2019-07-31 | 2022-03-22 | Hoffmann La Roche | Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção |
| MX2022003212A (es) | 2019-09-18 | 2022-04-25 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso. |
| CN110669137B (zh) | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
| JP2023501394A (ja) | 2019-11-15 | 2023-01-18 | エフ．ホフマン－ラ ロシュ アーゲー | タンパク質水溶液中での可視粒子形成の防止 |
| CN114867532A (zh) | 2019-12-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
| JP7296467B2 (ja) | 2019-12-18 | 2023-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体 |
| EP4081294A2 (en) | 2019-12-23 | 2022-11-02 | Genentech, Inc. | Apolipoprotein l1-specific antibodies and methods of use |
| EP4090666A1 (en) | 2020-01-15 | 2022-11-23 | F. Hoffmann-La Roche AG | Methods to decrease impurities from recombinant protein manufacturing processes |
| KR20220159426A (ko) | 2020-03-26 | 2022-12-02 | 제넨테크, 인크. | 감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포 |
| CN115380217A (zh) | 2020-04-08 | 2022-11-22 | 豪夫迈·罗氏有限公司 | 大分子非特异性清除测定 |
| JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ． ホフマン－ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
| CN115605185A (zh) | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司（Ch） | 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途 |
| MX2022015206A (es) | 2020-06-08 | 2023-01-05 | Hoffmann La Roche | Anticuerpos anti-hbv y metodos de uso. |
| CN115698084A (zh) | 2020-06-19 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
| CN115916826A (zh) | 2020-06-19 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 与CD3和FolR1结合的抗体 |
| WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
| CN115916825A (zh) | 2020-06-19 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 与cd3和cd19结合的抗体 |
| EP4172192A1 (en) | 2020-06-24 | 2023-05-03 | Genentech, Inc. | Apoptosis resistant cell lines |
| CN116133689A (zh) | 2020-07-07 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 作为治疗性蛋白质制剂的稳定剂的替代表面活性剂 |
| JP2023534458A (ja) | 2020-07-17 | 2023-08-09 | ジェネンテック， インコーポレイテッド | 抗Ｎｏｔｃｈ２抗体及び使用方法 |
| KR20230056766A (ko) | 2020-08-28 | 2023-04-27 | 제넨테크, 인크. | 숙주 세포 단백질의 CRISPR/Cas9 다중 녹아웃 |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| JP2023542079A (ja) | 2020-09-21 | 2023-10-05 | ジェネンテック， インコーポレイテッド | 多重特異性抗体の精製 |
| IL301366A (en) | 2020-09-24 | 2023-05-01 | Hoffmann La Roche | Mammalian cell lines with genetic knockout |
| AR123855A1 (es) | 2020-10-20 | 2023-01-18 | Genentech Inc | Anticuerpos anti-mertk conjugados con peg y métodos de uso |
| WO2022116141A1 (zh) * | 2020-12-04 | 2022-06-09 | 上海复旦张江生物医药股份有限公司 | 抗体药物偶联物、其中间体、制备方法及应用 |
| IL303656A (en) | 2020-12-17 | 2023-08-01 | Hoffmann La Roche | ANTI-HLA-G antibodies and their use |
| JP2024501662A (ja) | 2020-12-22 | 2024-01-15 | エフ． ホフマン－ラ ロシュ アーゲー | Ｘｂｐ１を標的とするオリゴヌクレオチド |
| EP4288458A1 (en) | 2021-02-03 | 2023-12-13 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
| JP2024513474A (ja) | 2021-04-09 | 2024-03-25 | エフ． ホフマン－ラ ロシュ アーゲー | 異種ポリペプチドを発現する細胞クローンを選択するための方法 |
| CA3215965A1 (en) | 2021-04-19 | 2022-10-27 | Amy Shen | Modified mammalian cells |
| KR20240010469A (ko) | 2021-05-21 | 2024-01-23 | 제넨테크, 인크. | 관심 재조합 생성물의 생성을 위한 변형된 세포 |
| CN113278071B (zh) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| KR20240021859A (ko) | 2021-06-18 | 2024-02-19 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ccl2 항체 |
| US20230197278A1 (en) | 2021-07-13 | 2023-06-22 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
| KR20240036570A (ko) | 2021-07-22 | 2024-03-20 | 에프. 호프만-라 로슈 아게 | 이종이량체 Fc 도메인 항체 |
| WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
| CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
| CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| WO2023094282A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Quantification of low amounts of antibody sideproducts |
| AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
| WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
| US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
| WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
| WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
| WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
| WO2024079015A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and imids |
| WO2024079009A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and proteasome inhibitors |
| WO2024079010A1 (en) | 2022-10-10 | 2024-04-18 | F. Hoffmann-La Roche Ag | Combination therapy of a gprc5d tcb and cd38 antibodies |
| WO2024079069A1 (en) | 2022-10-12 | 2024-04-18 | F. Hoffmann-La Roche Ag | Method for classifying cells |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| NZ521540A (en) * | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| AU2002240751A1 (en) * | 2001-03-09 | 2002-09-24 | William Herman | Targeted ligands |
| CN1555411A (zh) | 2001-08-03 | 2004-12-15 | ���迨�����＼���ɷݹ�˾ | 抗体-依赖性细胞毒性增大的抗体糖基化变体 |
| EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR101001243B1 (ko) | 2001-12-27 | 2010-12-17 | 글리코파이, 인크. | 포유동물-유형 탄수화물 구조의 설계 방법 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| JP4628679B2 (ja) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞 |
| ES2347325T3 (es) | 2002-09-12 | 2010-10-28 | Greenovation Biotech Gmbh | Metodo de produccion de proteinas. |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AU2003294912B2 (en) | 2002-12-20 | 2009-06-04 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| NZ541503A (en) | 2003-01-22 | 2008-09-26 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function |
| EP1639009B1 (en) * | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| AU2005267720B2 (en) | 2004-08-05 | 2012-02-23 | Genentech, Inc. | Humanized anti-cmet antagonists |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| EP2402374A1 (en) | 2005-02-07 | 2012-01-04 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| AU2006218876A1 (en) * | 2005-02-28 | 2006-09-08 | Centocor, Inc. | Heterodimeric protein binding compositions |
| CA2633486C (en) * | 2005-12-16 | 2015-02-03 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| EP1981532A4 (en) * | 2005-12-21 | 2010-06-30 | Medimmune Llc | EPHA2 MOLECULES AND USES THEREOF |
| JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
| US20090023189A1 (en) * | 2007-05-18 | 2009-01-22 | Applera Corporation | Apparatus and methods for preparation of subtantially uniform emulsions containing a particle |
| US20090155275A1 (en) * | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) * | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) * | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010034441A1 (en) * | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
| EP2417159A1 (en) * | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-3/anti-c-met antibodies |
| MX2011010158A (es) * | 2009-04-07 | 2011-10-17 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-2/anti-c-met. |
| KR101456326B1 (ko) * | 2009-04-07 | 2014-11-12 | 로슈 글리카트 아게 | 3가, 이중특이적 항체 |
| WO2010117457A2 (en) * | 2009-04-08 | 2010-10-14 | Applied Biosystems, Llc | System comprising dual-sided thermal cycler and emulsion pcr in pouch |
| RU2570633C2 (ru) * | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
| US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| RU2570554C2 (ru) | 2009-08-31 | 2015-12-10 | Роше Гликарт Аг | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью |
| HUE029026T2 (en) | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | Anti-HER3 antibodies and their applications |
| HUE036077T2 (hu) | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| BR112013013311A2 (pt) * | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | agente terapêutico de indução de citotoxicidade |
| WO2015096063A1 (en) * | 2013-12-25 | 2015-07-02 | Coyote Bioscience Co., Ltd. | Methods and systems for nucleic acid amplification |
| US10443086B2 (en) * | 2013-12-31 | 2019-10-15 | University Of Maryland, College Park | Methods, devices and systems for emulsion/droplet PCR |
| TW201641687A (zh) * | 2014-12-31 | 2016-12-01 | 卡尤迪生物科技（北京）有限公司 | 用于進行化學反應的設備和方法 |
| CN104846100B (zh) * | 2015-05-24 | 2017-10-10 | 北京工业大学 | 一种可用于微滴数字pcr的微滴制备方法 |
| CN104928368A (zh) * | 2015-05-24 | 2015-09-23 | 北京工业大学 | 一种利用硅油的适用于微滴数字pcr的微滴制备方法 |
| CN105256013B (zh) * | 2015-09-29 | 2018-08-31 | 上海市农业科学院 | 一种同步检测猪羊牛动物源性成分的微滴pcr引物体系及检测方法 |
-
2012
- 2012-08-21 US US13/591,028 patent/US20130058937A1/en not_active Abandoned
- 2012-08-21 ES ES12755967T patent/ES2686327T3/es active Active
- 2012-08-21 AU AU2012298535A patent/AU2012298535A1/en not_active Abandoned
- 2012-08-21 RS RS20181021A patent/RS57744B1/sr unknown
- 2012-08-21 LT LTEP12755967.2T patent/LT2748202T/lt unknown
- 2012-08-21 PT PT12755967T patent/PT2748202T/pt unknown
- 2012-08-21 DK DK12755967.2T patent/DK2748202T3/en active
- 2012-08-21 HU HUE12755967A patent/HUE039703T2/hu unknown
- 2012-08-21 RU RU2014109039A patent/RU2650775C2/ru active
- 2012-08-21 SI SI201231373T patent/SI2748202T1/sl unknown
- 2012-08-21 CN CN201280041665.6A patent/CN103764681B/zh active Active
- 2012-08-21 JP JP2014526467A patent/JP5925893B2/ja active Active
- 2012-08-21 MX MX2014001916A patent/MX349095B/es active IP Right Grant
- 2012-08-21 KR KR1020147004606A patent/KR101721301B1/ko active IP Right Grant
- 2012-08-21 SG SG2014008577A patent/SG2014008577A/en unknown
- 2012-08-21 BR BR112014003598-9A patent/BR112014003598B1/pt active IP Right Grant
- 2012-08-21 CA CA2844538A patent/CA2844538C/en active Active
- 2012-08-21 WO PCT/EP2012/066213 patent/WO2013026831A1/en active Application Filing
- 2012-08-21 MY MYPI2014700384A patent/MY171038A/en unknown
- 2012-08-21 PL PL12755967T patent/PL2748202T3/pl unknown
- 2012-08-21 EP EP12755967.2A patent/EP2748202B1/en active Active
- 2012-08-22 AR ARP120103070A patent/AR087615A1/es not_active Application Discontinuation
-
2014
- 2014-01-20 IL IL230553A patent/IL230553B/en active IP Right Grant
- 2014-10-28 HK HK14110799A patent/HK1197249A1/xx unknown
-
2016
- 2016-10-20 US US15/298,675 patent/US20170198043A1/en active Pending
-
2017
- 2017-08-07 AU AU2017210666A patent/AU2017210666A1/en not_active Abandoned
-
2018
- 2018-08-24 HR HRP20181355TT patent/HRP20181355T1/hr unknown
-
2019
- 2019-07-22 AU AU2019206138A patent/AU2019206138A1/en not_active Abandoned
-
2021
- 2021-08-23 AU AU2021221376A patent/AU2021221376A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087615A1 (es) | Moleculas biespecificas de union a antigeno | |
| PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| PE20211696A1 (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20180046A1 (es) | Anticuerpos terapeuticos y sus usos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| AR105724A1 (es) | Anticuerpos anti-bcma (antígeno de maduración de células b), moléculas de unión a antígenos biespecifícas que se unen a bcma y cd3 (determinante agregado 3), y usos de éstas | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| CO2020000357A2 (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
| UA116192C2 (uk) | Активуюча т-клітини біоспецифічна антигензв'язуюча молекула | |
| CO2018004094A2 (es) | Polipéptidos de unión a cd3 | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| PE20200384A1 (es) | Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| PE20211396A1 (es) | Receptores quimericos de dll3 y metodos para su uso | |
| AR100680A1 (es) | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos | |
| AR117728A1 (es) | Moléculas superagonistas de unión al antígeno cd28 con diana tumoral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FC | Refusal |